New Inhaled Antibiotic Cayston Now Available for People with CF

A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy. 

| 2 min read

Cayston® is the first CF drug to advance - from beginning to end - through the Cystic Fibrosis Foundation's Therapeutics Development Program.

Cayston, formerly known as AZLI, is for the treatment of Pseudomonas aeruginosa. It was approved by the U.S. Food and Drug Administration last week.

If you are interested in Cayston, talk to your CF doctor.

Cayston is administered with a new device called the Altera® Nebulizer System that allows patients to take the medicine in less than five minutes, a fraction of the time required for other inhaled antibiotics. It is the first new inhaled antibiotic developed for CF in more than a decade.

To support CF patients, Gilead Sciences, Inc., maker of Cayston, is launching a Cayston Access Program, a call center established with a nonprofit subsidiary of the Cystic Fibrosis Foundation.

The program helps people with CF and members of their care team with insurance verification, co-pay assistance and claims support. For information, visit www.Cayston.com or call 1-877-7CAYSTON (877-722-9786).

For most patients with private insurance, the prescription cost will be limited to a co-pay of $25, as a result of Gilead's support.
 
If you do not have insurance, Gilead has a special program that offers Cayston free to individuals with CF who meet the eligibility criteria. To learn more, call the Cayston Access Program.
 
The CF Foundation played an important role in the development of Cayston.

Additional Resources

Share this article
Topics
Antibiotics
Recent news
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
More Than 160 Advocates Raise Their Voices for PASTEUR Act During March on the Hill
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe